

Supplemental Amendment
U.S.S.N. 09/292,217
Page 2 of 6

Sub E1
D1
1. (Three Times Amended) A method of inducing a cytotoxic immune response against a solid tumor in a mammal, the method comprising:

administering to a mammal a combination of (i) an immunoconjugate comprising an antibody binding site capable of binding a target antigen expressed on a target cell in a solid tumor and interleukin 2, and (ii) an angiogenesis inhibitor having binding affinity for $\alpha_v\beta_3$ integrin,

wherein the combination induces a cytotoxic immune response against the solid tumor that is greater than a response induced by the immunoconjugate alone.

D2
8. (Three Times Amended) The method of claim 1, wherein the immunoconjugate is a fusion protein comprising, in an amino-terminal to carboxy-terminal direction, (i) the antibody binding site comprising an immunoglobulin variable region capable of binding a target antigen expressed on a target cell in a solid tumor, an immunoglobulin CH1 domain, an immunoglobulin CH2 domain, and (ii) interleukin 2.

Sub E2
D3
20. (Three Times Amended) A composition for inducing an immune response against a solid tumor in a mammal, the composition comprising in combination:

(i) an immunoconjugate comprising an antibody binding site capable of binding a target antigen expressed on a target cell in a solid tumor and interleukin-2, and (ii) an angiogenesis inhibitor having binding affinity for $\alpha_v\beta_3$ integrin,

wherein the combination induces a cytotoxic immune response against the solid tumor that is greater than a response induced by the immunoconjugate alone.

D4
23. (Three Times Amended) The composition of claim 20, wherein the immunoconjugate is a fusion protein comprising, in an amino-terminal to carboxy-terminal direction, (i) the antibody binding site comprising an immunoglobulin variable region capable of binding a target antigen expressed on a target cell in a solid tumor, an immunoglobulin CH1 domain, an immunoglobulin CH2 domain, and (ii) interleukin-2.

D5
36. (Three Times Amended) The method of claim 31, wherein the immunoconjugate is a fusion protein comprising, in an amino-terminal to carboxy-terminal direction, (i) the antibody

Supplemental Amendment
U.S.S.N. 09/292,217
Page 3 of 6

D5

binding site comprising an immunoglobulin variable region capable of binding a target antigen expressed on a target cell in a solid tumor, an immunoglobulin CH2 domain, and (ii) interleukin-2.
